Back to news centre >

How to Prevail Over Common Bottlenecks in Recombinant Protein Development

Early CDMO involvement can be the difference between a scalable gene therapy program and costly development setbacks. Discover how collaborative AAV manufacturing strategies help optimize processes, improve product quality, streamline regulatory pathways, and accelerate time-to-clinic. Explore the benefits of moving beyond the traditional vendor relationship toward a true development partnership.

By 3PBIOVIAN’s USP Development and Technical Service teams

Decisions made early in recombinant protein development have lasting impacts on product quality, manufacturability, timelines, and cost. In fact, many common chemistry, manufacturing, and controls (CMC) challenges can be mitigated or completely avoided through cross-functional collaboration early in a recombinant protein program.

Choosing the right expression system is the first of these key decisions, requiring alignment between molecule complexity, quality expectations, productivity, and downstream manufacturing considerations. From there, developers…

Complete the form to access the full PDF and discover practical strategies for accelerating your gene therapy program.

How To Prevail Over Common Bottlenecks

Please fill in the form for access to the download.

"*" indicates required fields

By submitting this form, 3P BIOPHARMACEUTICALS, S.L.U. will use the personal data you provide us with to send you the requested information.

*